Cited by 1,021SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 epidemiological studies

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Open access

Ibarrondo, F. Javier, Fulcher, Jennifer A., Goodman-Meza, David, Elliott, Julie, Hofmann, Christian, Hausner, Mary A., Ferbas, Kathie G., Tobin, Nicole H., Aldrovandi, Grace M., Yang, Otto O.·2020·New England Journal of Medicine

DOI 10.1056/nejmc2025179PMC PMC7397184

Open this paper in CoChat — free account

Abstract

Covid-19 Antibodies after Mild Infection Among 34 volunteers who had recovered from mild Covid-19 illness, antiviral antibodies to the receptor-binding domain of the viral spike protein declined wi...

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmc2025179

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup
Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Roubidoux, E. K., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 635
Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367
Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A Virus
Andraud, M., Lejeune, O., Musoro, J. Z., Ogunjimi, B., Beutels, P., & Hens, N. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002418 · Cited by 75
Longitudinal Analysis of Severe Acute Respiratory Syndrome (SARS) Coronavirus-Specific Antibody in SARS Patients
Chang, S., Wang, J., Huang, L., Chen, Y., Fang, C., Sheng, W., Wang, J., Yu, C., & Yang, P. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.12.1455-1457.2005 · Cited by 32

Flagged first, then by citations

Show all 5 references

Sorted by citations

Items 101–200 of 1,002

The immunology of SARS-CoV-2 infections and vaccines
Grigoryan, L., & Pulendran, B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101422 · Cited by 102
The Importance and Challenges of Identifying SARS-CoV-2 Reinfections
Babiker, A., Marvil, C. E., Waggoner, J. J., Collins, M. H., & Piantadosi, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02769-20 · Cited by 98
Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
An, X., Martinez-Paniagua, M. A., Rezvan, A., Sefat, S. R., Fathi, M., Singh, S., Biswas, S., Pourpak, M., Yee, C., Liu, X., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103037 · Cited by 98
The Power of Antibody-Based Surveillance
Alter, G., & Seder, R. A. (2020) · New England Journal of Medicine · doi:10.1056/nejme2028079 · Cited by 97
Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
Elslande, J. V., Oyaert, M., Lorent, N., Weygaerde, Y. V., Pottelbergh, G. V., Godderis, L., Ranst, M. A. V., André, E., Padalko, E. Y., Lagrou, K., et al. (2022) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2022.115659 · Cited by 95
Old vaccines for new infections: exploiting innate immunity to control COVID-19 and prevent future pandemics
Chumakov, K., Avidan, M. S., Benn, C. S., Bertozzi, S. M., Blatt, L., Chang, A. Y., Jamison, D. T., Khader, S. A., Kottilil, S., Netea, M. G., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101718118 · Cited by 96
Loss of Anti–SARS-CoV-2 Antibodies in Mild Covid-19
Bölke, E., Matuschek, C., & Fischer, J. C. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2027051 · Cited by 95
Children’s role in the COVID-19 pandemic: a systematic review of early surveillance data on susceptibility, severity, and transmissibility
Gaythorpe, K. A. M., Bhatia, S., Mangal, T. D., Unwin, H. J. T., Imai, N., Cuomo-Dannenburg, G., Walters, C. E., Jauneikaite, E., Bayley, H., Kont, M. D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92500-9 · Cited by 94
Determinants and Trends of COVID-19 Vaccine Hesitancy and Vaccine Uptake in a National Cohort of US Adults: A Longitudinal Study
Rane, M. S., Kochhar, S., Poehlein, E., You, W., Robertson, M. M., Zimba, R., Westmoreland, D. A., Romo, M. L., Kulkarni, S., Chang, M., et al. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab293 · Cited by 102
Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study
den Hartog, G., Vos, E. R. A., van den Hoogen, L. L., van Boven, M., Schepp, R. M., Smits, G., van Vliet, J., Woudstra, L., Wijmenga-Monsuur, A. J., van Hagen, C. C. E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab172 · Cited by 92
Durable SARS-CoV-2 B cell immunity after mild or severe disease
Ogega, C. O., Skinner, N., Blair, P. W., Park, H.-S., Littlefield, K. E., Ganesan, A., Dhakal, S., Ladiwala, P., Antar, A. A. R., Ray, S. C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145516 · Cited by 91
Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice
Wang, W., Huang, B., Zhu, Y., Tan, W., & Zhu, M. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00643-6 · Cited by 90
Seroprevalence of IgG antibodies against SARS-CoV-2 – a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020
Herzog, S. A., Bie, J. D., Abrams, S., Wouters, I., Ekinci, E., Patteet, L., Coppens, A., Spiegeleer, S. D., Beutels, P., Damme, P. V., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.9.2100419 · Cited by 89
B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 101
Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2
Grzelak, L., Velay, A., Madec, Y., Gallais, F., Staropoli, I., Schmidt‐Mutter, C., Wendling, M.-J., Meyer, N., Planchais, C., Rey, D., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab127 · Cited by 90
SARS‐CoV‐2 antibodies: IgA correlates with severity of disease in early COVID‐19 infection
Zervou, F. N., Louie, P., Stachel, A. G., Zacharioudakis, I. M., Ortiz‐Mendez, Y., Thomas, K. M., & Aguero‐Rosenfeld, M. E. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27058 · Cited by 87
Testing for SARS-CoV-2 antibodies
Watson, J., Richter, A. G., & Deeks, J. J. (2020) · BMJ · doi:10.1136/bmj.m3325 · Cited by 85
Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland
West, E., Anker, D., Amati, R., Richard, A., Wisniak, A., Butty, A., Albanese, E., Bochud, M., Chioléro, A., Crivelli, L., et al. (2020) · International Journal of Public Health · doi:10.1007/s00038-020-01494-0 · Cited by 85
Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset
Xiang, T., Liang, B., Fang, Y., Lu, S., Li, S., Wang, H., Li, H., Yang, X., Shěn, S., Zhu, B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708523 · Cited by 84
An Effective COVID-19 Vaccine Needs to Engage T Cells
Sauer, K., & Harris, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.581807 · Cited by 85
Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect
Maine, G. N., Lao, K. M., Krishnan, S. M., Afolayan-Oloye, O. I., Fatemi, S., Kumar, S., VanHorn, L., Hurand, A., Sykes, E., & Sun, Q. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104663 · Cited by 81
Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
Favresse, J., Gillot, C., Chiaro, L. D., Eucher, C., Elsen, M., Eeckhoudt, S. V., David, C., Morimont, L., Dogné, J., & Douxfils, J. (2021) · Viruses · doi:10.3390/v13071364 · Cited by 85
Discrete SARS-CoV-2 antibody titers track with functional humoral stability
Bartsch, Y. C., Fischinger, S., Siddiqui, S. M., Chen, Z., Yu, J., Gebre, M., Atyeo, C., Gorman, M. J., Zhu, A. L., Kang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21336-8 · Cited by 82
Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection
Jiang, X.-L., Wang, G.-L., Zhao, X.-N., Yan, F.-H., Lin, Y., Kou, Z.-Q., Ji, S.-X., Zhang, X.-L., Li, C.-B., Duan, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21155-x · Cited by 77
Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera
Oguntuyo, K. Y., Stevens, C. S., Hung, C.-T., Ikegame, S., Acklin, J. A., Kowdle, S., Carmichael, J. C., Chiu, H.-P., Azarm, K. D., Haas, G. D., et al. (2021) · mBio · doi:10.1128/mbio.02492-20 · Cited by 73
Estimating the Cumulative Incidence of SARS-CoV-2 Infection and the Infection Fatality Ratio in Light of Waning Antibodies
Shioda, K., Lau, M. S. Y., Kraay, A. N. M., Nelson, K., Siegler, A. J., Sullivan, P. S., Collins, M. H., Weitz, J. S., & Lopman, B. A. (2021) · Epidemiology · doi:10.1097/ede.0000000000001361 · Cited by 76
Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses
Ibarrondo, F. J., Hofmann, C., Fulcher, J. A., Goodman‐Meza, D., Mu, W., Hausner, M. A., Ali, A., Balamurugan, A., Taus, E., Elliott, J. E., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c03972 · Cited by 79
Self-citation
Immunity to SARS-CoV-2 up to 15 months after infection
Marcotte, H., Piralla, A., Zuo, F., Du, L., Cassaniti, I., Wan, H., Kumagai‐Braesch, M., Andréll, J., Percivalle, E., Sammartino, J. C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103743 · Cited by 83
Natural killer cell‐mediated ADCC in SARS‐CoV‐2‐infected individuals and vaccine recipients
Hagemann, K., Riecken, K., Jung, J. M., Hildebrandt, H., Menzel, S., Bunders, M. J., Fehse, B., Koch‐Nolte, F., Heinrich, F., Peine, S., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149470 · Cited by 76
Is coronavirus disease (COVID-19) seasonal? A critical analysis of empirical and epidemiological studies at global and local scales
Byun, W. S., Heo, S. W., Jo, G., Kim, J. W., Kim, S., Lee, S., Park, H. E., & Baek, J.-H. (2021) · Environmental Research · doi:10.1016/j.envres.2021.110972 · Cited by 81
COVID-19 spread in the UK: the end of the beginning?
Anderson, R. M., Hollingsworth, T. D., Baggaley, R. F., Maddren, R., & Vegvari, C. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31689-5 · Cited by 76
COVID-19—Lessons Learned and Questions Remaining
Fang, F. C., Benson, C. A., del Río, C., Edwards, K. M., Fowler, V. G., Fredricks, D. N., Limaye, A. P., Murray, B. E., Naggie, S., Pappas, P. G., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1654 · Cited by 78
Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
Tan, H., Juno, J. A., Lee, W. S., Barber-Axthelm, I. M., Kelly, H. G., Wragg, K. M., Esterbauer, R., Amarasena, T. H., Mordant, F. L., Subbarao, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21665-8 · Cited by 79
Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: A systematic review and meta‐analysis
Mekonnen, D. S., Mengist, H. M., Derbie, A., Nibret, E., Munshea, A., He, H., Li, B., & Jin, T. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2181 · Cited by 80
Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates
Boonyaratanakornkit, J. B., Morishima, C., Selke, S., Zamora, D., McGuffin, S. A., Shapiro, A. E., Campbell, V. L., McClurkan, C. L., Jing, L., Gross, R., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci144930 · Cited by 74
Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection of a Healthcare Worker in a Belgian Nosocomial Outbreak Despite Primary Neutralizing Antibody Response
Selhorst, P., van Ierssel, S. H., Michiels, J., Mariën, J., Bartholomeeusen, K., Dirinck, E. L., Vandamme, S., Jansens, H., & Ariën, K. K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1850 · Cited by 78
Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents
Koerber, N., Priller, A., Yazici, S., Bauer, T., Cheng, C., Mijočević, H., Wintersteller, H., Jeske, S. D., Vogel, E., Feuerherd, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27649-y · Cited by 75
The role of B cells in COVID-19 infection and vaccination
Chen, S., Guan, F., Candotti, F., Benlagha, K., Câmara, N. O. S., Herrada, A. A., James, L. K., Lei, J., Miller, H., Kubo, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988536 · Cited by 75
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
Louapre, C., Ibrahim, M., Maillart, É., Abdi, B., Papeix, C., Stankoff, B., Dubessy, A., Bensa, C., Créange, A., Chamekh, Z., et al. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326904 · Cited by 74
Refining “Long-COVID” by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection
Scherlinger, M., Felten, R., Gallais, F., Nazon, C., Chatelus, E., Pijnenburg, L., Mengin, A. C., Gras, A., Vidailhet, P., Arnould-Michel, R., et al. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00484-w · Cited by 82
Serological follow-up of SARS-CoV-2 asymptomatic subjects
Milani, G. P., Dioni, L., Favero, C., Cantone, L., Macchi, C., Delbue, S., Bonzini, M., Montomoli, E., Bollati, V., Albetti, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77125-8 · Cited by 74
Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution
Ravichandran, S., Lee, Y., Grubbs, G., Coyle, E. M., Klenow, L., Akasaka, O., Koga, M., Adachi, E., Saito, M., Nakachi, I., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf2467 · Cited by 71
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to NeutralizationPreprint
Weissman, D., Alameh, M., de Silva, T. I., Collini, P., Hornsby, H. R., Brown, R. L., LaBranche, C. C., Edwards, R. J., Sutherland, L. L., Santra, S., et al. (2020) · medRxiv · doi:10.1101/2020.07.22.20159905 · Cited by 72
Are we underestimating seroprevalence of SARS-CoV-2?
Burgess, S., Ponsford, M., & Gill, D. (2020) · BMJ · doi:10.1136/bmj.m3364 · Cited by 67
Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview
Ali, M. G., Zhang, Z., Gao, Q., Pan, M., Rowan, E. G., & Zhang, J. (2020) · Immunologic Research · doi:10.1007/s12026-020-09159-z · Cited by 71
Persistence of IgG response to SARS-CoV-2
Duysburgh, E., Mortgat, L., Barbezange, C., Dierick, K., Fischer, N., Heyndríckx, L., Hutse, V., Thomas, I., Gucht, S. V., Vuylsteke, B., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30943-9 · Cited by 68
Evolution of neurologic symptoms in non‐hospitalized COVID ‐19 “long haulers”
Ali, S. T., Kang, A. K., Patel, T. R., Clark, J. R., Perez-Giraldo, G., Orban, Z. S., Lim, P. H., Jimenez, M., Graham, E. L., Batra, A., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51570 · Cited by 70
Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma
Tso, F. Y., Lidenge, S. J., Poppe, L. K., Peña, P. B., Privatt, S. R., Bennett, S. J., Ngowi, J. R., Mwaiselage, J., Belshan, M., Siedlik, J. A., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0247640 · Cited by 68
“Neutralizing antibody (nAb) responses have been shown to preferentially target the receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein (S), but the levels of nAb were variable in infected subjects and can undergo fairly rapid decay kinetics [5, 6].”
Background
Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection
Clarke, C., Prendecki, M. F., Dhutia, A., Gan, J. J. L., Edwards, C., Prout, V., Lightstone, L., Parker, E. L., Marchesin, F., Griffith, M. E., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.009 · Cited by 68
SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors
Terpos, E., Stellas, D., Rosati, M., Sergentanis, T. Ν., Hu, X., Politou, M., Pappa, V., Ntanasis‐Stathopoulos, I., Karaliota, S., Bear, J., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.010 · Cited by 68
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 64
Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection
Tan, Y., Liu, F., Xu, X., Ling, Y., Huang, W., Zhu, Z., Guo, M., Lin, Y., Fu, Z., Liang, D., et al. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0822-5 · Cited by 68
SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up
Moncunill, G., Mayor, A. G., Santano, R., Jiménez, A., Vidal, M., Tortajada, M., Sanz, S., Méndez, S., Llupià, A., Aguilar, R., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa696 · Cited by 67
Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers
Harris, R., Whitaker, H., Andrews, N. J., Aiano, F., Amin‐Chowdhury, Z., Flood, J. S., Borrow, R., Linley, E., Ahmad, S. S. Y., Stapley, L., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.03.015 · Cited by 64
Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya
Adetifa, I. M. O., Uyoga, S., Gitonga, J. N., Mugo, D., Otiende, M., Nyagwange, J., Karanja, H. K., Tuju, J., Wanjiku, P., Aman, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24062-3 · Cited by 67
Duration of post–COVID-19 symptoms is associated with sustained SARS-CoV-2–specific immune responses
Files, J. K., Sarkar, S., Fram, T., Boppana, S., Sterrett, S., Qin, K., Bansal, A., Long, D. M., Sabbaj, S., Kobie, J. J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151544 · Cited by 69
Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
Zhao, H., To, K. K., Lam, H., Zhou, X., Chan, J. F., Peng, Z., Lee, A. C.-Y., Cai, J., Chan, W.-M., Ip, J. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21825-w · Cited by 67
Defending against SARS-CoV-2: The T cell perspective
Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 67
Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection
Manisty, C., Treibel, T. A., Jensen, M. P., Semper, A. E., Joy, G., Gupta, R. K., Cutiño‐Moguel, T., Andiapen, M., Jones, J., Taylor, S. C., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103259 · Cited by 60
Antibody response patterns in COVID‐19 patients with different levels of disease severity in Japan
Imai, K., Kitagawa, Y., Tabata, S., Kubota, K., Nagura‐Ikeda, M., Matsuoka, M., Miyoshi, K., Sakai, J., Ishibashi, N., Tarumoto, N., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26899 · Cited by 63
The Fall in Antibody Response to SARS-CoV-2: a Longitudinal Study of Asymptomatic to Critically Ill Patients Up to 10 Months after Recovery
Peghin, M., Martino, M. D., Fabris, M., Palese, A., Visintini, E., Graziano, E., Gerussi, V., Bontempo, G., D’Aurizio, F., Biasotto, A., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01138-21 · Cited by 61
The systemic inflammatory landscape of COVID-19 in pregnancy: Extensive serum proteomic profiling of mother-infant dyads with in utero SARS-CoV-2
Foo, S., Cambou, M. C., Mok, T., Fajardo, V. M., Jung, K. L., Fuller, T. L., Chen, W., Kerin, T., Mei, J. Y., Bhattacharya, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100453 · Cited by 65
Self-citation
Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help
Pušnik, J., Richter, E., Schulte, B., Dolscheid‐Pommerich, R., Bode, C., Putensen, C., Hartmann, G., Alter, G., & Streeck, H. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109320 · Cited by 59
Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort
Warszawski, J., Beaumont, A., Seng, R., de Lamballerie, X. N., Rahib, D., Lydié, N., Slama, R., Durrleman, S., Raynaud, P., Sillard, P., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-021-06973-0 · Cited by 71
Anti-SARS-CoV-2 IgM/IgG antibodies detection using a patch sensor containing porous microneedles and a paper-based immunoassay
Bao, L., Park, J., Qin, B., & Kim, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-14725-6 · Cited by 67
High-resolution epitope mapping and characterization of SARS-CoV-2 antibodies in large cohorts of subjects with COVID-19
Haynes, W. A., Kamath, K., Bozekowski, J. D., Baum, E., Campbell, M., Casanovas‐Massana, A., Daugherty, P. S., Cruz, C. S. D., Dhal, A., Farhadian, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02835-2 · Cited by 60
Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in the San Diego-Tijuana border region
Strathdee, S. A., Abramovitz, D. A., Vera, A., Vera, C. F., Rangel, G., Artamónova, I., Chaillon, A., Ignacio, C. C., Calderón-Villarreal, A., Martin, N. K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260286 · Cited by 62
Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications
Stone, M., Grebe, E., Sulaeman, H., Germanio, C. D., Dave, H., Kelly, K. K., Biggerstaff, B. J., Crews, B. O., Tran, N. K., Jerome, K. R., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2803.211885 · Cited by 59
Prevalence of antibodies against SARS-CoV-2 according to socioeconomic and ethnic status in a nationwide Brazilian survey
Horta, B. L., da Silveira, M. F., Barros, A. J. D., Barros, F. C., Hartwig, F. P., Dias, M. D. S., Menezes, A. M. B., Hallal, P. R. C., & Victora, C. G. (2020) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2020.135 · Cited by 62
Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
Kim, Y., Kim, S., Park, S., Kim, E.-H., Yu, K.-M., Chang, J.-H., Kim, E. J., Casel, M. A. B., Rollon, R., Jang, S., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1872352 · Cited by 62
Reconstructing the course of the COVID-19 epidemic over 2020 for US states and counties: Results of a Bayesian evidence synthesis model
Chitwood, M. H., Russi, M., Gunasekera, K. S., Havumaki, J., Klaassen, F., Pitzer, V. E., Salomon, J. A., Swartwood, N. A., Warren, J. L., Weinberger, D. M., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010465 · Cited by 56
Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020
Hövener, C., Neuhauser, H. K., Rosario, A. S., Busch, M. A., Schlaud, M., Hoffmann, R. G., Gößwald, A., Koschollek, C., Hoebel, J., Allen, J., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.47.2001752 · Cited by 57
Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection
Giorgi, V. D., West, K. A., Henning, A. N., Chen, L. N., Holbrook, M. R., Gross, R., Liang, J. Y., Postnikova, E. N., Trenbeath, J. L., Pogue, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab295 · Cited by 65
Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients
Slezak, J. M., Bruxvoort, K. J., Fischer, H. J., Broder, B. I., Ackerson, B. K., & Tartof, S. Y. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.07.030 · Cited by 60
Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa
Margolin, E., Burgers, W. A., Sturrock, E. D., Mendelson, M., Chapman, R. E., Douglass, N., Williamson, A., & Rybicki, E. P. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00441-3 · Cited by 58
Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS‐CoV ‐2 infection*
Sheikh‐Mohamed, S., Sanders, E. C., Gommerman, J. L., & Tal, M. C. (2022) · Immunological Reviews · doi:10.1111/imr.13118 · Cited by 57
Demographic and occupational determinants of anti-SARS-CoV-2 IgG seropositivity in hospital staff
Martin, C. A., Patel, P., Goss, C., Jenkins, D. R., Price, A., Barton, L. M., Gupta, P., Zaccardi, F., Jerina, H., Duraisingham, S., et al. (2020) · Journal of Public Health · doi:10.1093/pubmed/fdaa199 · Cited by 53
SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy
Ferreras, C., Pascual-Miguel, B., Mestre‐Durán, C., Navarro‐Zapata, A., Villa, L. C., Martín-Cortázar, C., de Paz, R., Marcos, A., Vicario, J., Balas, A., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.620730 · Cited by 55
Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2
Yu, K. K. Q., Fischinger, S., Smith, M. T., Atyeo, C. G., Cizmeci, D., Wolf, C. R., Layton, E. D., Logue, J. K., Aguilar, M. S., Shuey, K. D., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146242 · Cited by 56
SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19
Glück, V., Grobecker, S., Tydykov, L., Salzberger, B., Glück, T., Weidlich, T., Bertok, M., Gottwald, C., Wenzel, J. J., Gessner, A., et al. (2021) · Infection · doi:10.1007/s15010-021-01598-6 · Cited by 55
Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2
Grandjean, L., Saso, A., Ortiz, A. T., Lam, T., Hatcher, J., Thistlethwayte, R., Harris, M., Best, T., Johnson, M., Wagstaffe, H. R., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab607 · Cited by 55
Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
Korosec, C. S., Farhang‐Sardroodi, S., Dick, D. W., Gholami, S., Ghaemi, M. S., Moyles, I. R., Craig, M., Ooi, H. K., & Heffernan, J. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-25134-0 · Cited by 59
Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection
Gerhards, C., Thiaucourt, M., Kittel, M., Becker, C., Ast, V., Hetjens, M., Neumaier, M., & Haselmann, V. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.080 · Cited by 51
Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection
Favresse, J., Eucher, C., Elsen, M., Gillot, C., Eeckhoudt, S. V., Dogné, J., & Douxfils, J. (2021) · Microorganisms · doi:10.3390/microorganisms9030556 · Cited by 54
Correlates of Vaccine-Induced Protection against SARS-CoV-2
Koch, T., Mellinghoff, S. C., Shamsrizi, P., Addo, M. M., & Dahlke, C. (2021) · Vaccines · doi:10.3390/vaccines9030238 · Cited by 57
Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New Zealand
Whitcombe, A. L., McGregor, R., Craigie, A., James, A., Charlewood, R., Lorenz, N., Dickson, J. M. J. J., Sheen, C. R., Koch, B., Fox‐Lewis, S., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1261 · Cited by 52
IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection
Choudhary, H. R., Parai, D., Dash, G. C., Peter, A., Sahoo, S. K., Pattnaik, M., Rout, U. K., Nanda, R. R., Pati, S., & Bhattacharya, D. (2021) · Infection · doi:10.1007/s15010-021-01651-4 · Cited by 54
COVID-19 and lombardy: TESTing the impact of the first wave of the pandemic
Perico, L., Tomasoni, S., Peracchi, T., Perna, A., Pezzotta, A., Remuzzi, G., & Benigni, A. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103069 · Cited by 53
SARS-CoV-2 Seroprevalence in Household Domestic Ferrets (Mustela putorius furo)
Giner, J., Villanueva‐Saz, S., Tobajas, A. P., Pérez, M. D., González, A. I., Verde, M., Yzuel, A., García‐García, A., Taleb, V., Lira‐Navarrete, E., et al. (2021) · Animals · doi:10.3390/ani11030667 · Cited by 56
The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study
Sharma, N., Sharma, P., Basu, S., Saxena, S., Chawla, R., Dushyant, K., Mundeja, N., Marak, Z., Singh, S. S., Singh, G., et al. (2021) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trab109 · Cited by 54
Mild SARS-CoV-2 Infections and Neutralizing Antibody Titers
Bonfante, F., Costenaro, P., Cantarutti, A., Chiara, C. D., Bortolami, A., Petrara, M. R., Carmona, F., Pagliari, M., Cosma, C., Cozzani, S., et al. (2021) · PEDIATRICS · doi:10.1542/peds.2021-052173 · Cited by 52
Multidisciplinary Center Care for Long COVID Syndrome–A Retrospective Cohort Study
Bailey, J. I., Lavelle, B., Miller, J. L., Jimenez, M., Lim, P. H., Orban, Z. S., Clark, J. R., TOMAR, R., Ludwig, A., Ali, S. T., et al. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.05.002 · Cited by 55
Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020)
Kim, D. S., Rowland‐Jones, S., & Gea‐Mallorquí, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571481 · Cited by 51
Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape
Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 50
SARS-CoV-2 Infection Hospitalization Rate and Infection Fatality Rate Among the Non-Congregate Population in Connecticut
Mahajan, S., Caraballo, C., Li, S., Dong, Y., Chen, L., Huston, S. K., Srinivasan, R., Redlich, C. A., Ko, A. I., Faust, J. S., et al. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.01.020 · Cited by 50
SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
Karachaliou, M., Moncunill, G., Espinosa, A., Castaño‐Vinyals, G., Rubio, R., Vidal, M., Jiménez, A., de la Torre, E. P., Carreras, A., Cortés, B., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02547-2 · Cited by 50
Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis
Deng, L., Li, P., Zhang, X., Jiang, Q., Turner, D. E., Zhou, C., Gao, Y., Qian, F., Zhang, C., Lu, H. J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24220-7 · Cited by 50
SARS-CoV-2–specific B- and T-cell immunity in a population-based study of young Swedish adults
Björkander, S., Du, L., Zuo, F., Ekström, S., Wang, Y., Wan, H., Sherina, N., Schoutens, L., Andréll, J., Andersson, N., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.10.014 · Cited by 49
Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status
Yu, E. D., Wang, E. W., Garrigan, E., Goodwin, B., Sutherland, A., Tarke, A., Chang, J., Gálvez, R. I., Mateus, J., Ramirez, S. I., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.02.003 · Cited by 45
Individuals cannot rely on COVID-19 herd immunity: Durable immunity to viral disease is limited to viruses with obligate viremic spread
Yewdell, J. W. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009509 · Cited by 48

Authors: Ibarrondo, F. J., Fulcher, J. A., Goodman-Meza, D., Elliott, J., Hofmann, C., Hausner, M. A., Ferbas, K. G., Tobin, N. H., Aldrovandi, G. M., & Yang, O. O.
Affiliations: University of California, Los Angeles (US)
David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA
Corresponding author: Yang, Otto O.
ORCID: Ibarrondo, F. Javier
Fulcher, Jennifer A.
Hofmann, Christian
Ferbas, Kathie G.
Tobin, Nicole H.
Aldrovandi, Grace M.
Yang, Otto O.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-09-10
Volume: 383
Issue: 11
Pages: 1085-1087
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmc2025179
PMC: PMC7397184
OpenAlex: W3044311014
Cited by: 1,021
References: 5
Citations by year: 2026: 12 · 2025: 28 · 2024: 36 · 2023: 92 · 2022: 198 · 2021: 476 · 2020: 177
FWCI: 30.93
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: McCarthy Family Foundation
AIDS Healthcare Foundation (Grant to OOY)
National Institutes of National Institute of Allergy and Infectious Diseases (AI124979, AI131879, AI140775, UM1AI068616, UM1AI068632, UM1AI106716)
Doris Duke Charitable Foundation (2019086)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Mental Health
James B. Pendleton Charitable Trust
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords: SARS-CoV-2, COVID-19 pandemic, antibody persistence, anti-spike antibodies, receptor binding domain, mild COVID-19, antibody waning
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Antibodies, Viral, Female, Humans, Immunoglobulin G, Male, Middle Aged, Pneumonia, Viral, Coronavirus Infections, Young Adult, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks